

DISCLOSURE DIVISION

TB
G

- ☒ **WAIVER REQUEST**
☐ **ANSWER**
☐ **RECONSIDERATION REQUEST**
☐ **UNTIMELY**

DATE: 10/1/2021

DOCKET #: 2021-862

Ashley Wimberley, Director
Disclosure Division

FILER INFORMATION

Name: Mr. Easton W. Shelvin
Address: 216 Sonny St., Opelousas, LA 70570-6637
Office/Position: St. Landry Parish Council / District 3 / St. Landry
of Disclosures/Amendments Filed with Agency: 11
Years Covered: 2015-2020
Final Report: No

REPORT INFORMATION

Name of Report: Tier 2 Annual Personal Financial Disclosure covering calendar year 2019 - Amendment
Report ID: PFD20006617
Original Due Date: 7/6/2020
Initial PFD Filed on: 5/15/2020
NOD-amend Received: 3/23/2021
NOD-amend Signed by: Agent-Mail Carrier - Signed as Corona 19/SWO C-6
Amendment/Answer Due Date based on NOD: 4/1/2021
Amendment/Answer Filed: 5/13/2021

LATE FEE INFORMATION

Amount of Late Fee: \$2500
Days late from receipt of NOD: 42
Total days late from initial due date: 311
Late Fee Order Received: 7/31/2021
Payment/Waiver Request Due Date: 8/20/2021
Waiver Request Received: 8/9/2021

COMMENTS:

Mr. Easton Shelvin submitted a Waiver Request for the late filing of his 2019 PFD Amendment. Mr. Shelvin stated in January 2021 he was diagnosed with COVID-19 and it was very difficult time. Due to his illness, he neglected to manage his mail and did not notice the NOD-Amend letter. When he opened the letter in May of 2021, he immediately faxed over his amendment report. Mr. Shelvin asks the Ethics Board to "please find mercy" and waive or suspend all of his late fee. He apologizes for the tardiness of his amendment filing.

OTHER LATE FEE INFORMATION

Disclosure Statements:

- Other Outstanding Statements: No
- Other Outstanding Late Fees: No
- Prior Late Fees: Yes - 2015 \$100 Paid
- Reassessed Late Fees: No

Campaign Finance:

- Outstanding Late Fees: No
- Prior Late Fees: No

To the Board of Ethic

I beseech you therefore, by the mercies of God that you would accept my plea for waiver or suspend late fees that have been assessed (Late Fee Assessment) Report PFD 20006617 to me. I do apologize by all means for my tardiness with an acceptable reason.

In January of this year 2021 I was diagnosed with COVID-19 and it was a challenging time, but thank God, I made it through. Due to those trying times, I mismanaged my mail, and did not for some reason or another receive or take notice of my prior notice of amendment until the month of May, when I immediately faxed over my amended copy. I beg this Board of Ethics to please find mercy for me, and waive or suspend all late fees. I do once again apologize for my tardiness, and ask that you would accept my plea.

If for any reason you may need to contact me for further information, please feel free to call me at (337-331-5226) or email (shelvin101@gmail.com).

Thanks In Advance
Easton W. Shelvin

Shelvin, Easton W, M, 10/08/1976

337-331-5226 MRN: 0000006606

Stacey W Mayeaux MD
 519 E PRUDHOMME ST, OPELOUSAS, LA 70570-6499
 337-878-3755

FINAL RESULT

Accession ID: GV143101

Lab Ref ID: 47128-148213

Order Date: 07/21/2021

Result Recd: 07/22/2021 10:10:05

Coll. Date: 07/21/2021 00:00:00

Report: 07/22/2021 10:05:12

Requesting Physician: Mayeaux, Stacey

Ordering Physician: Mayeaux, Stacey

SARS-CoV-2 IgG

NAME	VALUE	REFERENCE RANGE
F SARS-CoV-2 IgG INTERP	POSITIVE	NEGATIVE
F SARS-CoV-2 IgG	1.7	<1.4 (INDEX)
- IMPORTANT NOTES:		
- Test method is the Abbott Architect chemiluminescent microparticle		
- immunoassay (CMIA) for the qualitative detection of IgG antibodies		
- to SARS-CoV-2. The assay is designed to detect IgG antibodies to		
- the nucleocapsid protein of SARS-CoV-2 in serum and plasma from		
- patients with signs and symptoms of infection who are suspected of		
- coronavirus disease (COVID-19) or in serum and plasma of subjects		
- that may have been infected by SARS-CoV-2. Negative results do not		
- rule out SARS-CoV-2 infection, particularly in those who have been		
- in contact with the virus. Testing with a molecular diagnostic		
- should be considered to evaluate for active infection in these		
- individuals. Results from antibody testing should not be used as		
- the sole basis to diagnose or exclude SARS-CoV-2 infection or to		
- inform infection status. Test may not be informative after spike		
- antigen-based (mRNA, other) vaccines; consider test code 3609		
- SARS-CoV-2 IgG Ab, S protein assay.		
- www.cpllabs.com/COVID-19-IgG-Serology7301		
- UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT		
- CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX 78754		
- LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D.		
- CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01		

Shelvin, Easton W | 10/08/1976 | M

Accession ID: GV143101

Shelvin, Easton W, M, 10/08/1976

337-331-5226 MRN: 0000006606

Stacey W Mayeaux MD
519 E PRUDHOMME ST, OPELOUSAS, LA 70570-6499
337-678-3755

FINAL RESULT

Accession ID: EG669571

Lab Ref ID: EG669571

Order Date: 01/14/2021

Result Recd: 01/15/2021 18:40:03

Coll. Date: 01/14/2021 15:23:00

Report: 01/15/2021 18:35:52

Requesting Physician: Mayeaux, Stacey

Ordering Physician: Mayeaux, Stacey

SARS-COV-2(COVID19),HIGH RISK,RT-PCR

NAME	VALUE	REFERENCE RANGE
F SARS-CoV-2 INTERPRETATION	POSITIVE	SEE NOTE
- SARS-CoV-2 RNA DETECTED		
- Positive results are indicative of the presence of SARS-CoV-2 RNA;		
- clinical correlation with patient history and other diagnostic		
- information is necessary to determine patient infection status.		
- Positive results do not rule out bacterial infection or co-infection		
- with other viruses. Positive and negative predictive values of		
- testing are highly dependent on prevalence.		
F SOURCE	NOT SPECIFIED	
- Note: Methodology is Thermo-Fisher Real-Time RT-PCR. The expected		
- result or reference range is NEGATIVE (Not Detected).		
- For more information regarding COVID-19 testing to include clinical		
- information, methodology detail, intended use, FDA authorization and		
- recommended fact sheets for patients or healthcare providers, see New		
- Test Announcement: SARS-CoV-2 (COVID-19) by NAAT at URL below (note,		
- fact sheets are provided by method given in report:		
- https://www.cpllabs.com/clinicians/client-communications/		
- Alternatively, see downloadable PDF fact sheet at:		
- https://www.cpllabs.com/COVID-19-RT-PCR		
- UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT		
- CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX 78754		
- LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D.		
- CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01		

Shelvin, Easton W | 10/08/1976 | M

Accession ID: EG669571

Shelvin, Easton W, M, 10/08/1976

337-331-5226 MRN: 0000006606

Stacey W Mayeaux MD
519 E PRUDHOMME ST, OPELOUSAS, LA 70570-84E
337-678-375

FINAL RESULT

Accession ID: GV143101

Lab Ref ID: 47128-148213

Order Date: 07/21/2021

Result Recd: 07/22/2021 10:10:05

Coll. Date: 07/21/2021 00:00:00

Report: 07/22/2021 10:05:12

Requesting Physician: Mayeaux, Stacey

Ordering Physician: Mayeaux, Stacey

SARS-CoV-2 IgG

NAME	VALUE	REFERENCE RANGE
F SARS-CoV-2 IgG INTERP	POSITIVE	NEGATIVE
F SARS-CoV-2 IgG	1.7	<1.4 (INDEX)

- IMPORTANT NOTES:

- Test method is the Abbott Architect chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of IgG antibodies to SARS-CoV-2. The assay is designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2 in serum and plasma from patients with signs and symptoms of infection who are suspected of coronavirus disease (COVID-19) or in serum and plasma of subjects that may have been infected by SARS-CoV-2. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Testing with a molecular diagnostic should be considered to evaluate for active infection in these individuals. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. Test may not be informative after spike antigen-based (mRNA, other) vaccines; consider test code 3609 SARS-CoV-2 IgG Ab, S protein assay.

- www.cpllabs.com/COVID-19-IgG-Serology7301

- UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT

- CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX 78754

- LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D.

- CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01

Shelvin, Easton W | 10/08/1976 | M

Accession ID: GV143101

Shelvin, Easton W, M, 10/08/1976

337-331-5226 MRN: 0000008606

Stacey W Mayeaux IV
519 E PRUDHOMME ST, OPELOUSAS, LA 70570-84
337-678-37**FINAL RESULT**

Accession ID: EG669571

Lab Ref ID: EG669571

Order Date: 01/14/2021

Result Recd: 01/15/2021 18:40:03

Coll. Date: 01/14/2021 15:23:00

Report: 01/15/2021 18:35:52

Requesting Physician: Mayeaux, Stacey

Ordering Physician: Mayeaux, Stacey

SARS-COV-2(COVID19),HIGH RISK,RT-PCR

NAME	VALUE	REFERENCE RANGE
F SARS-CoV-2 INTERPRETATION	POSITIVE	SEE NOTE
<ul style="list-style-type: none"> - SARS-CoV-2 RNA DETECTED - Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. - Positive results do not rule out bacterial infection or co-infection with other viruses. Positive and negative predictive values of testing are highly dependent on prevalence. 		
F SOURCE	NOT SPECIFIED	
<ul style="list-style-type: none"> - Note: Methodology is Thermo-Fisher Real-Time RT-PCR. The expected result or reference range is NEGATIVE (Not Detected). - For more information regarding COVID-19 testing to include clinical information, methodology detail, intended use, FDA authorization and recommended fact sheets for patients or healthcare providers, see New Test Announcement: SARS-CoV-2 (COVID-19) by NAAT at URL below (note, fact sheets are provided by method given in report: https://www.cpllabs.com/clinicians/client-communications/ Alternatively, see downloadable PDF fact sheet at: https://www.cpllabs.com/COVID-19-RT-PCR - UNLESS OTHERWISE INDICATED, ALL TESTING PERFORMED AT CLINICAL PATHOLOGY LABORATORIES, INC. 9200 WALL ST AUSTIN, TX 78754 - LABORATORY DIRECTOR: MARK A. SILBERMAN, M.D. - CLIA NUMBER 45D0505003 CAP ACCREDITATION NO. 21525-01 		

Shelvin, Easton W | 10/08/1976 | M

Accession ID: EG669571



Paul Mouton, Marshal
City of Opelousas & Ward I of St Landry Parish
PO Box 1999—Opelousas, Louisiana
70571-1999
Phone (337) 948-2577 Ext 119
Fax (337) 948-6759

DATE SENT: 8/9/2021

NO. OF PAGES 5
(INCLUDING COVER SHEET)

TO: NAME: Ashley Wimberly

FIRM/OFFICE: Louisiana Board of Ethics

FAX NO. (225) 381-7271

FROM: Easton Shelum
MARSHAL'S OFFICE

FAX NO. 337-948-6759

COMMENTS:

Here is my request for late fee Assessment-Report OFD 20006617
to be waived or suspended.

I have attached with my request my doctor's report.

Thank you kindly



Unknown @Port 9100

08/09/2021 12:36 PM

Start Page

Xerox® VersaLink™ B405DN Multifunction Printer